Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tradipitant - Vanda Pharmaceuticals

Drug Profile

Tradipitant - Vanda Pharmaceuticals

Alternative Names: LY-686017; VLY 686

Latest Information Update: 13 Sep 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer Eli Lilly and Company; National Institute on Alcohol Abuse and Alcoholism; Vanda Pharmaceuticals
  • Class Anti-inflammatories; Antipruritics; Antivirals; Anxiolytics; Chlorobenzenes; Gastrokinetics; Pyridines; Small molecules; Triazoles
  • Mechanism of Action Neurokinin 1 receptor antagonists; Substance P inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Atopic dermatitis; COVID 2019 infections; Gastroparesis
  • Phase II Motion sickness; Pruritus
  • Discontinued Alcoholism; Social phobia

Most Recent Events

  • 31 Aug 2020 Vanda Pharmaceuticals plans to file a NDA for Gastroparesis in USA, in the second half of 2021
  • 31 Aug 2020 Vanda Pharmaceuticals plans to launch tradipitant for Gastroparesis in USA, in the second half of 2021
  • 31 Aug 2020 Adverse events data from preclinical trials released by Vanda Pharmaceuticals
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top